Clinical Commander

Back to dossier
cardio.hypertensive-emergency.amphetamine-withdrawal.v1PRODUCTION
cardio.hypertensive-emergency.amphetamine-withdrawal.v1

Amphetamine / stimulant WITHDRAWAL hypertensive crisis (rebound HTN + autonomic instability + tachy + diaphoresis + tremor + agitation/depression overlap 6-72 h after abrupt cessation of chronic stimulant therapy or use)

cardiologyacuteadult
Hard-required inputs
0 / 13
Care setting:

Encounter flow

10/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Stimulant withdrawal HTN crisis = abrupt cessation of chronic stimulant use → autonomic instability + rebound NE release (recovery faster than receptor upregulation reverses) → HTN + tachy + diaphoresis + tremor + agitation overlap with depression ("crash") 6-72 h post cessation. Pharmacology pivot: BENZODIAZEPINE FIRST for sympatholysis + agitation/anxiety; nicardipine IV for HTN; phentolamine for severe; CCB acceptable; AVOID isolated β-blocker monotherapy (unopposed alpha principle); CONSIDER stimulant restart if clearly iatrogenic (held during OR, rehab admission) or arrange gradual taper if planned discontinuation. Distinguish from active intoxication crisis (active-use toxidrome) and clonidine withdrawal (different mechanism). Route to parent engine for shared HTN-emergency arc; this dossier owns the withdrawal-specific pharmacology + SUD treatment + psychiatric care.

Inputs
5
Actions
0
Advance rule
Set
Advance when

stimulant withdrawal etiology confirmed by history + cessation timing 6-72 h

Patient inputs (14)

Younger users (20-45) most affected for illicit stimulant withdrawal; older patients on long-term prescription stimulants for ADHD increasingly recognized for iatrogenic withdrawal

Confirms etiology — type (meth, amphetamine, MDMA, prescription Adderall/Vyvanse/Ritalin), route (smoked/IV/snorted/oral), dose, duration of chronic use, last use timestamp; chronic users at higher rebound risk

Confirms timing of last dose + reason for cessation (NPO for OR, refill issue, deliberate stop, rehab admission, supply interruption); guides resumption strategy + future taper plan

Depression + suicide ideation prominent in stimulant withdrawal "crash" phase; PHQ-9 + Columbia Suicide Severity Rating Scale (CSSRS); high-acuity psychiatric care often needed

Differentiates from active intoxication (less severe agitation in withdrawal vs intoxication); guides benzo titration

Demand ischemia rule-out; QTc baseline; arrhythmia (AF) common in chronic stimulant cardiomyopathy

Demand ischemia in CAD or chronic-stimulant cardiomyopathy; serial q3-6h × 2

Confirms recent stimulant use (amphetamine class detection window 1-3 d); helps distinguish withdrawal (recent use cleared or clearing) from active intoxication (high-level recent use); cross-reactivity with pseudoephedrine + MDMA + cathinones noted

eGFR drives drug dosing; baseline for renal injury; chronic stimulant use can cause CKD

Defines crisis threshold; drives titration of nicardipine + phentolamine; rebound HTN typically less sustained than active-use crisis but distinct entity

Component of MAP; DBP >120 supports crisis criterion + alpha-overdrive severity

Rebound tachycardia from autonomic instability; HR often 100-130 even at rest; risk of demand ischemia in CAD or chronic-stimulant cardiomyopathy

Hyperthermia uncommon in withdrawal (more typical of active intoxication); helps differentiate from active stimulant toxidrome

Chronic stimulant cardiomyopathy screen — global hypokinesis, often EF <40% in long-term users (Schürer JACC 2017 PMID 28473131); partially reversible with sustained abstinence

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (4)

4 need judgement
  • informationallife_threateningsevere_withdrawal_with_active_suicide_ideation
    Stimulant withdrawal "crash" phase with active suicide ideation, plan, or intent — psychiatric emergency requiring 1:1 sitter + emergent psychiatry + safety planning
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevererecurrent_withdrawal_cycle_indicating_active_use_pattern
    Patient with multiple prior stimulant withdrawal crises in setting of active or relapsing use pattern — recurrent cycle suggests untreated StUD requiring intensification + consideration of residential treatment
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverebeta_blocker_exposure_error_worsening_withdrawal_HTN
    Patient received β-blocker (metoprolol/esmolol/propranolol) before stimulant-withdrawal HTN crisis recognized → paradoxical worsening due to unopposed alpha (same principle as cocaine + meth + clonidine withdrawal)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereiatrogenic_prescription_stimulant_withdrawal_during_hospitalization_or_OR
    Patient on chronic prescription stimulant (Adderall, Vyvanse, Ritalin) for ADHD had medication held during hospitalization, perioperative period, or rehab admission without taper plan → withdrawal HTN crisis (preventable)
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

TREATMENTrequiredDrives monitoring threshold
Loading…

Recommended regimen

Amphetamine / stimulant withdrawal HTN crisis — benzodiazepine FIRST + nicardipine + phentolamine; AVOID isolated β-blocker; consider stimulant restart if iatrogenic; psychiatric care for depression + suicide risk; long-term contingency management for StUD
axis: amphetamine_withdrawal_htn_crisis_pharmacology
Selected axis "Amphetamine / stimulant withdrawal HTN crisis — benzodiazepine FIRST + nicardipine + phentolamine; AVOID isolated β-blocker; consider stimulant restart if iatrogenic; psychiatric care for depression + suicide risk; long-term contingency management for StUD" by default fallback (first axis)
  • lorazepam
    first line
    benzodiazepine
    1-2 mg IV q5-10 min, repeat to effect • IV • PRN q5-10 min then scheduled
    triggers: stimulant_withdrawal_HTN_crisis, agitation_anxiety_dysphoria
    AHA 2008 Class I PMID 18391116 + AHA 2024 stimulant update — sympatholytic + reduces HTN + reduces tachy + treats agitation/anxiety/dysphoria; first-line in withdrawal HTN crisis (extends from active-use framework)
    rxcui 6470
  • diazepam
    first line
    benzodiazepine
    5-10 mg IV q5-10 min • IV • PRN
    triggers: benzodiazepine_alternative
    Longer half-life alternative to lorazepam; useful for sustained sympatholysis
    rxcui 3322
  • nicardipine
    first line
    dihydropyridine_ccb
    5 mg/h IV titrate q5-15 min by 2.5 mg/h, max 15 mg/h • IV • continuous infusion
    triggers: HTN_persistent_after_benzo
    AHA 2025 HTN emergency Class I — first-line non-dissection HTN crisis; predictable titration; vasodilation reverses alpha-driven vasoconstriction
    rxcui 7396
  • phentolamine
    second line
    alpha_adrenergic_blocker
    1-5 mg IV q5-15 min titrate • IV • PRN bolus
    triggers: severe_rebound_HTN_failed_benzo_and_nicardipine, concurrent_beta_blocker_unopposed_alpha_rescue
    Pure alpha-blocker reverses rebound NE-driven alpha-vasoconstriction; rescue for unopposed alpha if concurrent β-blocker exposure error
    rxcui 8153
  • nitroglycerin
    second line
    organic_nitrate
    5-200 mcg/min IV titrate q3-5 min • IV • continuous
    triggers: concurrent_chest_pain_or_pulm_edema
    Vasodilator + coronary vasodilator; useful for demand ischemia or LV-failure overlay
    rxcui 4917
  • verapamil
    second line
    non_dihydropyridine_ccb
    5-10 mg IV slow push q15-30 min • IV • PRN
    triggers: CCB_alternative, rate_control_with_HTN_overlap
    Negus Circulation 1994 — verapamil reverses cocaine vasospasm; framework extends to stimulant withdrawal
    rxcui 11170
  • mirtazapine
    add on
    tetracyclic_antidepressant
    15-30 mg PO at bedtime • PO • nightly
    triggers: stimulant_withdrawal_with_depression_and_insomnia_component
    Coffin JAMA Psychiatry 2020 PMID 32049330 — modest benefit in methamphetamine use disorder; addresses depression + insomnia + craving components of withdrawal
    rxcui 15996
  • bupropion
    add on
    norepinephrine_dopamine_reuptake_inhibitor
    150 mg PO daily × 3 d → 300 mg PO daily • PO • daily
    triggers: stimulant_use_disorder_long_term_treatment_with_depression
    Trivedi NEJM 2021 PMID 33497547 — naltrexone-bupropion combo modest benefit in methamphetamine use disorder; bupropion alone helpful for depression component
    rxcui 42347
  • naltrexone
    add on
    opioid_antagonist
    50 mg PO daily OR 380 mg IM monthly • PO or IM • daily or monthly
    triggers: stimulant_use_disorder_long_term_treatment_with_combo_bupropion
    Trivedi 2021 — naltrexone-bupropion combination has modest benefit; consider after acute crisis resolution
    rxcui 7243
  • AVOID isolated β-blocker without α-blockade or benzo first
    contraindication substitute
    do_not_use
    AVOID • N/A • N/A
    triggers: stimulant_withdrawal_confirmed
    Lange NEJM 1989 PMID 2522592 + AHA 2008 PMID 18391116 — same unopposed-alpha pharmacological principle as cocaine + meth + clonidine withdrawal; isolated β-blockade leaves alpha-vasoconstriction unopposed
  • CONSIDER stimulant restart if clearly iatrogenic (prescription Adderall/Vyvanse/Ritalin held during OR, rehab, or hospitalization)
    first line
    iatrogenic_correction
    Restart at lower dose with planned taper over 1-2 weeks if discontinuation planned, or resume home dose if continuation planned • PO • per home schedule
    triggers: iatrogenic_withdrawal_from_held_prescription_stimulant
    For iatrogenic withdrawal, restart corrects the underlying cause; planned discontinuation needs supervised gradual taper coordinated with prescriber + perioperative protocol for future surgeries
  • CONTINGENCY MANAGEMENT for stimulant use disorder
    first line
    behavioral_intervention
    Per program protocol • behavioral • per program
    triggers: stimulant_use_disorder_long_term_treatment
    Connors Annu Rev Clin Psychol 2018 PMID 29494256 — strongest RCT evidence for StUD treatment; no FDA-approved MAT exists; evidence-based first-line non-pharmacologic intervention

outpatient playbook — drug actions (3)

  1. 1. maintain antihypertensive regimen if baseline HTN
    rxcui 17767
    titrated to BP target • PO • daily
    trigger: sustained maintenance
    ACC/AHA 2025
  2. 2. continue StUD pharmacotherapy if engaged
    rxcui 42347
    bupropion + naltrexone maintenance • PO + IM • daily/monthly
    trigger: continued treatment
    Trivedi 2021
  3. 3. manage prescription stimulant if continued for ADHD
    rxcui 237205
    lowest effective dose with periodic reassessment + perioperative protocol • PO • daily
    trigger: ongoing ADHD treatment
    Coordinate with psychiatry/PCP; advance-supply system + perioperative protocol mandatory

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Abrupt cessation of chronic stimulant use (methamphetamine, amphetamine, MDMA, prescription stimulant such as Adderall/lisdexamfetamine/methylphenidate at high chronic doses) within last 6-72 h + SBP ≥180 / DBP ≥120 + autonomic instability features; HTN + tachycardia + diaphoresis + tremor + agitation overlap with depressive features ("crash" phase) 6-72 h after stimulant cessation; Prescription amphetamine derivative (Adderall, Vyvanse, Ritalin) held during hospitalization, rehab admission, OR perioperative period without taper plan → withdrawal HTN crisis (preventable).

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Amphetamine / stimulant WITHDRAWAL hypertensive crisis (rebound HTN + autonomic instability + tachy + diaphoresis + tremor + agitation/depression overlap 6-72 h after abrupt cessation of chronic stimulant therapy or use)** (cardio.hypertensive-emergency.amphetamine-withdrawal.v1).
Scope: Stimulant withdrawal HTN crisis = abrupt cessation of chronic stimulant use → autonomic instability + rebound NE release (recovery faster than receptor upregulation reverses) → HTN + tachy + diaphoresis + tremor + agitation overlap with depression ("crash") 6-72 h post cessation. Pharmacology pivot: BENZODIAZEPINE FIRST for sympatholysis + agitation/anxiety; nicardipine IV for HTN; phentolamine for severe; CCB acceptable; AVOID isolated β-blocker monotherapy (unopposed alpha principle); CONSIDER stimulant restart if clearly iatrogenic (held during OR, rehab admission) or arrange gradual taper if planned discontinuation. Distinguish from active intoxication crisis (active-use toxidrome) and clonidine withdrawal (different mechanism). Route to parent engine for shared HTN-emergency arc; this dossier owns the withdrawal-specific pharmacology + SUD treatment + psychiatric care.

No severity triggers fired against current inputs.

Plan

Regimen axis: **Amphetamine / stimulant withdrawal HTN crisis — benzodiazepine FIRST + nicardipine + phentolamine; AVOID isolated β-blocker; consider stimulant restart if iatrogenic; psychiatric care for depression + suicide risk; long-term contingency management for StUD**.
1. lorazepam 1-2 mg IV q5-10 min, repeat to effect IV PRN q5-10 min then scheduled (benzodiazepine, first line) — AHA 2008 Class I PMID 18391116 + AHA 2024 stimulant update — sympatholytic + reduces HTN + reduces tachy + treats agitation/anxiety/dysphoria; first-line in withdrawal HTN crisis (extends from active-use framework)
2. diazepam 5-10 mg IV q5-10 min IV PRN (benzodiazepine, first line) — Longer half-life alternative to lorazepam; useful for sustained sympatholysis
3. nicardipine 5 mg/h IV titrate q5-15 min by 2.5 mg/h, max 15 mg/h IV continuous infusion (dihydropyridine_ccb, first line) — AHA 2025 HTN emergency Class I — first-line non-dissection HTN crisis; predictable titration; vasodilation reverses alpha-driven vasoconstriction
4. phentolamine 1-5 mg IV q5-15 min titrate IV PRN bolus (alpha_adrenergic_blocker, second line) — Pure alpha-blocker reverses rebound NE-driven alpha-vasoconstriction; rescue for unopposed alpha if concurrent β-blocker exposure error
5. nitroglycerin 5-200 mcg/min IV titrate q3-5 min IV continuous (organic_nitrate, second line) — Vasodilator + coronary vasodilator; useful for demand ischemia or LV-failure overlay
6. verapamil 5-10 mg IV slow push q15-30 min IV PRN (non_dihydropyridine_ccb, second line) — Negus Circulation 1994 — verapamil reverses cocaine vasospasm; framework extends to stimulant withdrawal
7. mirtazapine 15-30 mg PO at bedtime PO nightly (tetracyclic_antidepressant, add on) — Coffin JAMA Psychiatry 2020 PMID 32049330 — modest benefit in methamphetamine use disorder; addresses depression + insomnia + craving components of withdrawal
8. bupropion 150 mg PO daily × 3 d → 300 mg PO daily PO daily (norepinephrine_dopamine_reuptake_inhibitor, add on) — Trivedi NEJM 2021 PMID 33497547 — naltrexone-bupropion combo modest benefit in methamphetamine use disorder; bupropion alone helpful for depression component
9. naltrexone 50 mg PO daily OR 380 mg IM monthly PO or IM daily or monthly (opioid_antagonist, add on) — Trivedi 2021 — naltrexone-bupropion combination has modest benefit; consider after acute crisis resolution
10. AVOID isolated β-blocker without α-blockade or benzo first AVOID N/A N/A (do_not_use, contraindication substitute) — Lange NEJM 1989 PMID 2522592 + AHA 2008 PMID 18391116 — same unopposed-alpha pharmacological principle as cocaine + meth + clonidine withdrawal; isolated β-blockade leaves alpha-vasoconstriction unopposed
11. CONSIDER stimulant restart if clearly iatrogenic (prescription Adderall/Vyvanse/Ritalin held during OR, rehab, or hospitalization) Restart at lower dose with planned taper over 1-2 weeks if discontinuation planned, or resume home dose if continuation planned PO per home schedule (iatrogenic_correction, first line) — For iatrogenic withdrawal, restart corrects the underlying cause; planned discontinuation needs supervised gradual taper coordinated with prescriber + perioperative protocol for future surgeries
12. CONTINGENCY MANAGEMENT for stimulant use disorder Per program protocol behavioral per program (behavioral_intervention, first line) — Connors Annu Rev Clin Psychol 2018 PMID 29494256 — strongest RCT evidence for StUD treatment; no FDA-approved MAT exists; evidence-based first-line non-pharmacologic intervention

Setting playbook (outpatient) — Long-term PCP + cardiology + addiction medicine + psychiatry coordination — sustained BP target, abstinence maintenance, psychiatric stability, no recurrent withdrawal events, perioperative protocol invoked for any future surgery
13. maintain antihypertensive regimen if baseline HTN titrated to BP target PO daily — sustained maintenance (ACC/AHA 2025)
14. continue StUD pharmacotherapy if engaged bupropion + naltrexone maintenance PO + IM daily/monthly — continued treatment (Trivedi 2021)
15. manage prescription stimulant if continued for ADHD lowest effective dose with periodic reassessment + perioperative protocol PO daily — ongoing ADHD treatment (Coordinate with psychiatry/PCP; advance-supply system + perioperative protocol mandatory)

Non-pharmacologic actions:
- Contingency management long-term enrollment
- Support group attendance
- Harm reduction continued counseling
- Annual mental health screening
- Perioperative protocol templated in chart for any planned surgery

AVOID / contraindication checks:
- Isolated_beta_blocker_avoid_in_stimulant_withdrawal_use_benzo_first (Lange NEJM 1989 PMID 2522592 + AHA 2008 PMID 18391116)
- Concurrent_beta_blocker_worsens_stimulant_rebound (taper β blocker before stimulant restart if both being managed)
- Stimulant_restart_only_if_iatrogenic_with_supervised_taper_plan (do not restart for active StUD)
- Psychiatric_safety_screen_required_before_discharge (high suicide risk during early abstinence)
- Nicardipine_avoid_severe_aortic_stenosis_or_advanced_HF
- Reduce_drug_doses_in_CKD_eGFR_below_30
- Benzo_caution_in_elderly_or_concurrent_opioid_use_respiratory_depression

Monitoring

Regimen monitoring:
- continuous ECG q15min BP minimum 24h (AHA 2025 HTN)
- serial troponin q3-6h x2 if chest pain or chronic stimulant CMP
- mental status and suicide risk assessment q2h
- CIWA or stimulant withdrawal scale q4h
- benzo titration to symptoms not just BP
- psychiatry consult within 24h for co-occurring depression
- addiction medicine consult during admission
- echo at 3-6 mo if chronic cardiomyopathy to assess reversibility with abstinence

Setting (outpatient) monitoring:
- Quarterly BP
- Annual ECG + lipid + A1c
- Annual echo if cardiomyopathy
- Quarterly PHQ-9 + suicide risk
- Annual medication review

Follow-up plan: Stimulant use disorder (StUD) treatment — CONTINGENCY MANAGEMENT has strongest RCT evidence (Connors Annu Rev Clin Psychol 2018 PMID 29494256); no FDA-approved MAT for StUD (mirtazapine + naltrexone-bupropion combo modest benefit per Trivedi NEJM 2021 PMID 33497547 + Coffin JAMA Psychiatry 2020 PMID 32049330); cardiology follow-up if MI/cardiomyopathy occurred; ECHO at 3-6 months to assess for chronic stimulant cardiomyopathy reversibility with abstinence (Schürer JACC 2017); BP regimen if persistent HTN; psychiatric care for depression component (high suicide risk during early abstinence — close follow-up); harm reduction; HIV/HCV screening; PrEP if applicable; support groups (NA/CA, SMART Recovery); IF prescription-stimulant iatrogenic withdrawal — coordinate with prescriber for supervised taper plan + advance-supply system + perioperative protocol
- Close-out criterion: StUD treatment booked (contingency management + behavioral therapy + psychiatry) + cardiology + repeat echo at 3-6 mo if cardiomyopathy + perioperative protocol if iatrogenic

Monitoring phase: Continuous ECG + telemetry; q15-30 min BP × 24 h; serial troponin q3-6h × 2 if chest pain or chronic CMP; suicide watch if active ideation; mental status + agitation scale q2h; CIWA or stimulant-equivalent withdrawal scale; benzo titration to symptoms not just BP

Disposition

Current setting: outpatient — Long-term PCP + cardiology + addiction medicine + psychiatry coordination — sustained BP target, abstinence maintenance, psychiatric stability, no recurrent withdrawal events, perioperative protocol invoked for any future surgery

Disposition criteria:
- Long-term continuation; cross-link to cardio.htn.core.v1 + cardio.htn.resistant.v1 for chronic management; psych for ongoing care

Escalation triggers (move to higher acuity):
- Recurrent withdrawal events → addiction medicine + multidisciplinary
- Suicide ideation recurrence → emergent psychiatry
- BP rebound → urgent visit

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Stimulant withdrawal "crash" phase with active suicide ideation, plan, or intent — psychiatric emergency requiring 1:1 sitter + emergent psychiatry + safety planning
- [SEVERE] Patient with multiple prior stimulant withdrawal crises in setting of active or relapsing use pattern — recurrent cycle suggests untreated StUD requiring intensification + consideration of residential treatment
- [SEVERE] Patient received β-blocker (metoprolol/esmolol/propranolol) before stimulant-withdrawal HTN crisis recognized → paradoxical worsening due to unopposed alpha (same principle as cocaine + meth + clonidine withdrawal)

Citations

- 2025 ACC/AHA HTN Guideline (Whelton) + AHA 2024 stimulant cardiotoxicity (Manja Circulation 2024) + SAMHSA TIP 33 (2021) + Trivedi NEJM 2021 PMID 33497547 (naltrexone-bupropion for methamphetamine StUD) [PMID:33497547](https://pubmed.ncbi.nlm.nih.gov/33497547/)
- Cited evidence (PMID 32049330) [PMID:32049330](https://pubmed.ncbi.nlm.nih.gov/32049330/)
- Cited evidence (PMID 29494256) [PMID:29494256](https://pubmed.ncbi.nlm.nih.gov/29494256/)
- Cited evidence (PMID 28473131) [PMID:28473131](https://pubmed.ncbi.nlm.nih.gov/28473131/)
- Cited evidence (PMID 18391116) [PMID:18391116](https://pubmed.ncbi.nlm.nih.gov/18391116/)

Last reconciled with current guidelines: 2026-05-15.
References
  • 2025 ACC/AHA HTN Guideline (Whelton) + AHA 2024 stimulant cardiotoxicity (Manja Circulation 2024) + SAMHSA TIP 33 (2021) + Trivedi NEJM 2021 PMID 33497547 (naltrexone-bupropion for methamphetamine StUD) — PMID:33497547
  • Cited evidence (PMID 32049330) — PMID:32049330
  • Cited evidence (PMID 29494256) — PMID:29494256
  • Cited evidence (PMID 28473131) — PMID:28473131
  • Cited evidence (PMID 18391116) — PMID:18391116